Results 111 to 120 of about 55,011 (304)

Regulation of Insulin Secretion Through Long‐Chain Fatty Acid Receptors

iNew Medicine, EarlyView.
Stefan Offermanns
wiley   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology

Научно-практическая ревматология
Glucagon-like peptide-1 receptor agonists (ArGLP-1) are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immunoinflammatory diseases suggest important pleiotropic mechanisms of ...
Е. L. Nasonov, Т. S. Panevin, Е. А. Troshina   +2 more
doaj   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research

Frontiers in Medicine
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a prevalent and severe global hepatic disorder, necessitating the development of effective therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), along
Xinyi Lu, Li Yang
doaj   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature

Open Medicine
Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.
Zhang Yuchen, Li Anxin
doaj   +1 more source

Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists

Journal of Diabetes Investigation, 2019
Aims/Introduction Research has proved a correlation between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and gastrointestinal adverse events.
Megumi Shiomi, Tesshu Takada, Yoichi Tanaka, Keiko Yajima, Akira Isomoto, Masaki Sakamoto, Katsuya Otori   +6 more
doaj   +1 more source

Review for "Number needed to treat in cardiovascular outcome trials with glucagon‐like peptide‐1 receptor agonists: A systematic review with temporal analysis"

, 2020
Salvatore Carbone
openalex   +1 more source

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. [PDF]

, 2019
Mice were treated with a fully human monoclonal glucagon receptor antagonistic antibody REMD2.59 following myocardial infarction or pressure overload.
Baal, Ulysis, Gao, Chen, Lu, John, Ren, Shuxun Vincent, Thai, Dung, Wang, Yibin, Yan, Hai, Yu, Junyi, Zeng, Chunyu   +8 more
core